EFNA2 Knockout HAP1 Polyclonal Cells provide a CRISPR/Cas9-edited polyclonal knockout cell population designed for targeted disruption of the EFNA2 gene in the HAP1 host background. This near-haploid, fibroblast-like cell line enables functional interrogation of ephrin-A2, a glycosylphosphatidylinositol (GPI)-anchored ligand that engages Eph receptor tyrosine kinases. The polyclonal format ensures a diverse pool of gene-edited cells, facilitating robust loss-of-function analyses without single-cell clonal selection. By eliminating ephrin-A2 expression, these cells serve as a versatile platform for dissecting ephrin-Eph signaling networks, cell adhesion dynamics, and migratory behavior in a genetically simplified model system.
HAP1 cells are a haploid human cell line derived from the chronic myeloid leukemia KBM-7 clone, exhibiting adherent, fibroblast-like morphology. Their near-haploid karyotype streamlines functional genomics screens by reducing genetic redundancy, thereby enhancing the resolution of gene-trait associations. This attribute renders HAP1 an ideal host for CRISPR-mediated knockout studies, particularly in signaling pathways where allele dosage or compensatory paralogs might obscure phenotypic outcomes. In the context of EFNA2 disruption, the HAP1 background offers a clean canvas to examine ephrin-A2-dependent processes without interference from wild-type alleles, enabling clear attribution of observed effects to the targeted locus.
EFNA2 encodes ephrin-A2, a cell-surface GPI-linked ligand that activates EphA and EphB receptors, including EphA4, EphB2, EphA3, and EphA7. Ligand-receptor engagement triggers bidirectional signaling: forward signaling through Eph kinase activity and reverse signaling through ephrin-mediated pathways. Ephrin-A2 binding to EphA4 induces receptor phosphorylation, subsequently activating Src family kinases, RhoA, and focal adhesion kinase (FAK), which converge on cytoskeletal regulators such as paxillin. These signals modulate cell adhesion, migration, and repulsive guidance cues. Upstream regulators like Wnt signaling, PAX6, MEIS1, and HOXA9 control EFNA2 expression, while ADAM10 metalloprotease facilitates ephrin-A2 shedding, adding a layer of post-translational control. Thus, EFNA2 knockout disrupts a pivotal node in the ephrin signaling axis, with implications for axon guidance, cancer cell invasion, and tissue boundary formation.
In the HAP1 model, EFNA2 knockout cells provide a powerful tool for investigating ephrin-A2 biology within the context of chronic myeloid leukemia derivation and haploid genetics. The simplified genomic landscape minimizes confounding variables, making these cells particularly suitable for synthetic lethality screens, drug sensitivity profiling, and genome-wide modifier studies. Researchers can employ this knockout model to dissect ephrin-A2-mediated cell adhesion and migration pathways relevant to cancer progression, neurological disorders, and cardiovascular anomalies. Furthermore, the polyclonal nature supports pool-based assays, such as adhesion or invasion screens, without the bias of clonal variation, offering a more representative population-level readout of gene disruption effects.
Typical research applications include cancer invasion studies using migration and invasion assays, axon guidance mechanism investigations via immunostaining for focal adhesion markers like paxillin and co-immunoprecipitation of Eph-ephrin complexes, and functional genomics screens for regulators of ephrin signaling. For example, western blotting can assess EphA4 phosphorylation status in EFNA2-depleted cells, while adhesion assays quantify changes in substrate attachment. These knockout polyclonal populations are ideal for high-throughput loss-of-function screens, enabling systematic mapping of ephrin-A2-dependent pathways in neurobiology and oncology. For technical specifications or ordering inquiries, please contact Ascent Research.
